# US 2023/0055208 A1 · A pharmaceutical oral dosage form of q203

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2023/0055208 A1
- Document ID: US20230055208A1
- Status: Published application
- Kind: A1
- Application number: 17/780,969
- Filed: 2020-12-17
- Published: 2023-02-23
- Earliest claimed: 2019-12-20
- Assignees: Qurient Co., Ltd.
- Applicants: Qurient Co., Ltd.
- Inventors: KIYEAN NAM; JAESEUNG KIM; CHUNWON JUNG; SAEYEON LEE
- Web page: https://patentgrep.com/patent/US20230055208A1

## CPC

- A61K 9/2054: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/437: the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
- A61K 9/2009: {Inorganic compounds}
- A61K 9/2013: {Organic compounds, e.g. phospholipids, fats}
- A61K 9/2018: {Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates}
- A61K 9/2027: {obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates}
- A61K 9/2077: {Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets}
- A61K 9/2095: {Tabletting processes}
- A61K 9/2866: {Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose}
- A61K 31/4545: containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
- A61K 47/26: Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
- A61K 47/32: Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers {, poly(meth)acrylates, or polyvinyl pyrrolidone}
- A61K 47/38: Cellulose; Derivatives thereof
- A61P 31/04: Antibacterial agents
- A61P 31/06: for tuberculosis
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to new pharmaceutical dosage forms of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide, in particular of its ditosylate form.

## Claims

### Claim 1

A pharmaceutical oral dosage form of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate, said dosage form comprising a mixture of:
a) granules comprising 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl) piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate, at least one intragranular pharmaceutically acceptable excipient, and a solubilizer; and
b) a blend surrounding said granules and comprising at least one binder, at least one lubricant and at least one disintegrant, and optionally a filler.

### Claim 2 (depends on 1)

The pharmaceutical oral dosage form according to claim 1, wherein said at least one intragranular pharmaceutically acceptable excipient is selected from a binder, a filler and a combination of the two.

### Claim 3 (depends on 1)

The pharmaceutical oral dosage form according to claim 1, wherein said granules a) consist of 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate, a binder, a filler, and a solubilizer.

### Claim 4 (depends on 1)

The pharmaceutical oral dosage form according to claim 1, wherein said granules a) do not contain a lubricant and not a disintegrant or superdisintegrant.

### Claim 5 (depends on 2)

The pharmaceutical oral dosage form according to claim 2, wherein said binder in said granules a) is not: crosslinked starch, microcrystalline cellulose, crosslinked cellulose, crosslinked polyvinylpyrrolidone (crospovidone), crosslinked alginic acid, soy polysaccharide or calcium silicate.

### Claim 6 (depends on 2)

The pharmaceutical oral dosage form according to claim 2, wherein said binder in said granules a) is selected from acacia gum, gum tragacanth, gelatin, sucrose, starch, and non-crosslinked polyvinylpyrrolidone (PVP.

### Claim 7 (depends on 6)

The pharmaceutical oral dosage form according to claim 6, wherein said binder in said granules a) is present in said pharmaceutical dosage form in an amount of from about 0.1% by weight to 5% by weight.

### Claim 8 (depends on 2)

The pharmaceutical oral dosage form according to claim 2, wherein said filler in said granules a) is selected from mannitol, dextrose, dextrin, lactose, sorbitol, sucrose, and inositol.

### Claim 9 (depends on 8)

The pharmaceutical oral dosage form according to claim 8, wherein said filler in said granules a) is present in said pharmaceutical dosage form in an amount of from about 1.5% by weight to 25% by weight.

### Claim 10 (depends on 1)

The pharmaceutical oral dosage form according to claim 1, wherein said solubilizer in said granules a) is selected from D-α-tocopherol polyethylene glycol succinate (vitamin E-TPGS), sodium lauryl sulphate (SLS), polyoxyethylene sorbitan monooleate (Tween®), cetyltriamethylammonium bromide (CTAB), amino acids, and polyethylene glycol.

### Claim 11 (depends on 10)

The pharmaceutical oral dosage form according to claim 10, wherein said solubilizer in said granules a) is present in said pharmaceutical dosage form in an amount of from about 0.5% by weight to 8% by weight.

### Claim 12 (depends on 1)

The pharmaceutical oral dosage form according to claim 1, wherein said granules consist of, 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate, a binder which is non-crosslinked polyvinylpyrrolidone (PVP), a filler which is mannitol, and a solubilizer which is D-α-tocopherol polyethylene glycol succinate (vitamin E-TPGS).

### Claim 13 (depends on 1)

The pharmaceutical oral dosage form according to claim 1, wherein said at least one binder in said blend surrounding said granules b) is selected from starch, microcrystalline cellulose, povidone, hydroxypropyl cellulose, hydroxypropylmethyl cellulose and combinations thereof.

### Claim 14 (depends on 13)

The pharmaceutical oral dosage form according to claim 13, wherein said at least one binder in said blend surrounding said granules b) is present in said pharmaceutical dosage form in an amount of from about 25% by weight to 50% by weight.

### Claim 15 (depends on 1)

The pharmaceutical oral dosage form according to claim 1, wherein said at least one lubricant in said blend surrounding said granules b) is selected from magnesium stearate, calcium stearate, PEG6000, sodium stearyl stearate, sodium lauryl sulphate, colloidal silicon dioxide and combinations thereof.

### Claim 16 (depends on 15)

The pharmaceutical oral dosage form according to claim 15, wherein said at least one lubricant in said blend surrounding said granules b) is present in said pharmaceutical dosage form in an amount of from about 1% by weight to 5% by weight, wherein, when said at least one lubricant in said blend surrounding said granules b) is a combination of colloidal silicon dioxide and magnesium stearate, said colloidal silicon dioxide is present in said pharmaceutical dosage form in an amount of from about 0.5% by weight to 3.5% by weight, and wherein in such combination said magnesium stearate is present in said pharmaceutical dosage form in an amount of from about 0.1% by weight to 2% by weight.

### Claim 17 (depends on 1)

The pharmaceutical oral dosage form according to claim 1, wherein said at least one disintegrant in said blend surrounding said granules b) is selected from crosslinked starch, starch glycolate, microcrystalline cellulose, crosslinked cellulose, crosslinked polyvinylpyrrolidone (crospovidone), crosslinked alginic acid, croscarmellose, soy polysaccharide, and calcium silicate.

### Claim 18 (depends on 17)

The pharmaceutical oral dosage form according to claim 17, wherein said at least one disintegrant in said blend surrounding said granules b) is present in said pharmaceutical dosage form in an amount of from about 5% by weight to 12% by weight.

### Claim 19 (depends on 2)

The pharmaceutical oral dosage form according to claim 2, wherein said blend surrounding said granules comprises a filler, which is the same filler as the filler in said granules.

### Claim 20 (depends on 19)

The pharmaceutical oral dosage form according to claim 19, wherein said filler in said blend surrounding said granules is present in said pharmaceutical dosage form in an amount of from about 25% by weight to 50% by weight.

### Claim 21 (depends on 1)

The pharmaceutical oral dosage form according to claim 1, wherein said 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy) phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate is present in said pharmaceutical dosage form in an amount of from about 1% by weight to 35% by weight.

### Claim 22 (depends on 1)

The pharmaceutical oral dosage form according to claim 1, comprising a mixture of:
a) granules comprising 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy) phenyl) piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate in an amount of about 23-30% by weight of the dosage form, mannitol in an amount of about 15-25% by weight of the dosage form, polyvinylpyrrolidone in an amount of about 1-5% by weight of the dosage form, D-α-tocopherol polyethylene glycol succinate (vitamin E-TPGS) in an amount of about 5-8% by weight of the dosage form; and
b) a blend surrounding said granules and comprising microcrystalline cellulose in an amount of about 30-34% by weight of the dosage form, colloidal silicon dioxide in an amount of about 1-3% by weight of the dosage form, magnesium stearate in an amount of about 0.5-1.5% by weight of the dosage form, and croscarmellose sodium in an amount of about 7-10% by weight of the dosage form; or
c) granules comprising 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy) phenyl) piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate in an amount of about 12-15% by weight of the dosage form, mannitol in an amount of about 8-12% by weight of the dosage form, polyvinylpyrrolidone in an amount of 1-2% by weight of the dosage form, D-α-tocopherol polyethylene glycol succinate (vitamin E-TPGS) in an amount of about 2-5% by weight of the dosage form; and
d) a blend surrounding said granules and comprising microcrystalline cellulose in an amount of about 30-33% by weight of the dosage form, mannitol in an amount of about 30-33% by weight of the dosage form, magnesium stearate in an amount of about 0.5-1.5% by weight of the dosage form, and croscarmellose sodium in an amount of about 7-10% by weight of the dosage form; or
e) granules comprising 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy) phenyl) piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate in an amount of about 1-5% by weight of the dosage form, mannitol in an amount of about 1-3% by weight of the dosage form, polyvinylpyrrolidone in an amount of about 0.1-0.5% by weight of the dosage form, D-α-tocopherol polyethylene glycol succinate (vitamin E-TPGS) in an amount of about 0.5-0.8% by weight of the dosage form; and
f) a blend surrounding said granules and comprising microcrystalline cellulose in an amount of about 40-45% by weight of the dosage form, mannitol in an amount of about 40-45% by weight of the dosage form, magnesium stearate in an amount of about 0.5-1.5% by weight of the dosage form, and croscarmellose sodium in an amount of about 7-10% by weight of the dosage form.

### Claim 23 (depends on 1)

A process for preparing a pharmaceutical oral dosage form as defined in claim 1, wherein said process comprises:
i) granulating 6-chloro-2-ethyl-N-(4-(4-(4-(trifluoromethoxy)phenyl)piperidine-1-yl)benzyl)imidazo[1,2-a]pyridine-3-carboxamide ditosylate and the components of said granules a), as defined in claim 1, by a suitable granulation process;
ii) blending the granules obtained in step i) with the components of said blend, as defined in claim 1;
iii) compressing the mixture obtained in step ii) into a pharmaceutical dosage form; and, optionally
iv) coating the dosage form obtained in step iii).

### Claim 24 (depends on 23)

A pharmaceutical oral dosage form obtainable by a process as defined in claim 23.

### Claim 25 (depends on 1)

A method for the treatment of a bacterial infection wherein said treatment comprises administering, to a subject with the infection, a pharmaceutical oral dosage form according to claim 1.
